U.S. FDA Sets Advisory Date For MGI/Eisai's Aquavan
This article was originally published in PharmAsia News
Executive Summary
An FDA advisory committee in May will review MGI Pharma/Eisai's sedative hypnotic agent Aquavan, a drug eagerly awaited by health insurers looking to cut anesthetic costs in colonoscopy.